RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Oral Rivaroxaban Alone for Symptomatic Pulmonary Embolism
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 4
SP 21
OP 22
DO 10.1177/155989771204015
UL http://mdc.sagepub.com/content/12/4/21.abstract
AB Rivaroxaban, a direct, specific, competitive factor Xa inhibitor that inhibits thrombin generation, is an effective treatment for venous thromboembolism. The Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism trial [EINSTEIN PE; Buller HR et al. N Engl J Med 2012] reported data that showed that rivaroxaban was noninferior to standard therapy but had a superior bleeding profile in patients with pulmonary embolism.